Greywolf Therapeutics is developing antigen modulation technology that alters antigen presentation to enhance T cell recognition and targeting of diseased cells. This approach aims to improve treatment outcomes for patients with cancers, autoimmune disorders, and infectious diseases by addressing immune dysfunction at the cellular level.
Funding
$128.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers, autoimmune disorders, and infectious diseases are difficult to treat because T cells fail to recognize and target diseased cells effectively. This immune dysfunction stems from incorrect antigen presentation, preventing the immune system from identifying and eliminating affected cells.
Solution
Greywolf Therapeutics is developing antigen modulation technology designed to enhance T cell recognition and targeting of diseased cells. This technology modulates antigen presentation within cells, altering their appearance to the immune system and enabling T cells to identify and attack them more effectively. By addressing the initial step of T cell signaling, the approach aims to improve treatment outcomes across oncology, autoimmunity, and virology. The company's lead antigen modulator, GRWD5769, has demonstrated proof-of-mechanism and target engagement in a Phase 1/2 trial in oncology.
Target Audience
The primary target audience includes patients with cancers, autoimmune disorders, and infectious diseases, as well as healthcare providers seeking novel therapeutic approaches to address immune dysfunction.
Features
- Modulation of antigen presentation to enhance T cell recognition
- First-in-class ERAP1 inhibitor (GRWD5769) with demonstrated clinical results
- Active discovery and development programs across oncology, autoimmunity, and virology